Senate Bill No. 1324 authorizes emergency medical services (EMS) personnel to administer glucagon nasal powder, a medication used to treat severe hypoglycemia in individuals with diabetes. The bill defines "emergency medical services personnel" to include certified emergency medical responders, various classes of certified emergency medical technicians (EMTs), including advanced EMTs, and licensed paramedics. To administer glucagon nasal powder, EMS personnel must be trained according to national standards recognized by the Commissioner of Public Health and must determine that its use is necessary for the patient. The bill mandates that all EMS personnel receive this training from an organization designated by the commissioner and allows licensed or certified ambulances to carry glucagon nasal powder for administration.

The bill introduces new legal language, specifically stating that EMS personnel can administer glucagon nasal powder and detailing the training requirements. It does not delete any existing legal language but adds provisions to enhance the capabilities of EMS personnel in emergency situations. The potential fiscal impact includes costs for training and the acquisition of glucagon nasal powder, which is estimated to cost approximately $300 per unit. The ongoing fiscal implications will depend on the usage rate of the medication and inflation.